搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
来自MSN
1 天
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...
3 天
on MSN
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...
STAT
2 天
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...
BioSpace
1 天
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
2 天
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With ...
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...
FierceBiotech
2 天
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...
1 天
AbbVie’s Parkinson’s Drug Tavapadon: A Market Perform Rating Amidst Competitive ...
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...
The Pharma Letter
2 天
AbbVie’s tavapadon offers encouragement in Parkinson’s
AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...
McKnight's Long-Term Care News
2 天
Promising results from Parkinson’s drug trial
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...
Becker's Hospital Review
1 天
AbbVie drug shows promise in treating Parkinson's: 3 notes
The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...
Outsourcing-pharma
2 天
AbbVie announces positive phase 3 results for Parkinson’s drug
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
devdiscourse
2 天
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈